TARDBP and argyrophilic grain disease: None of the biomarkers investigated could predict any of the other co‐pathologies investigated (i.e., CAA, TDP‐43, LBD, and AGD), which replicates some of the results from a recent study in a different cohort with a subsample of the biomarkers described here (Smirnov et al, 2022).